Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma
{{output}}
Background: Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, with most patients diagnosed at advanced stages. Sorafenib, a multi-targeted tyrosine kinase inhibitor, remains a first-line therapy but has limited ef... ...
